#EGFRm

Osimertinib Plus Chemotherapy Significantly Extends Survival in Advanced EGFRm NSCLC Osimertinib plus chemotherapy significantly improves overall survival in EGFRm NSCLC, signaling a new standard of care.

Final OS data from FLAURA2 confirm osimertinib + platinum-based chemo significantly extends survival in 1L EGFRm NSCLC. A potential new standard of care. Read more: hubs.li/Q03y1gxQ0 #LungCancer #EGFRm #NSCLC #Oncology #ClinicalTrials